The finding that iloprost, in addition to the well-known vasodilator effect, can counteract CXCL10 release by human endothelial cells and fibroblasts, and associates with a significant lower chemokine blood level in SSc subjects, might open new scenarios for early treatments in SSc. This evidence concerns the gene CXCL10 and systemic sclerosis.